Patents Represented by Attorney Norman Dulak

Find this attorney in the Justia Lawyer Directory

  • Metal-interferon-alpha crystals
    Patent number: 5441734
    Abstract: The present invention provides for crystalline zinc-interferon alfa-2 (IFN .alpha.-2) having a monoclinic morphology. The present invention further provides for crystalline cobalt-IFN .alpha.-2, crystalline calcium-IFN .alpha.-2, and crystalline IFN .alpha.-2 having a serum half-life of at least about 12 hours when injected into a primate. The present invention further provides for a method for producing a crystalline IFN .alpha.-2 comprising forming a soluble metal-IFN .alpha.-2 complex, and equilibrating the soluble metal-IFN .alpha.-2 complex in solution with an acetate salt of the metal under conditions that will cause the metal-IFN .alpha.-2 solution to become supersaturated and form crystalline metal-IFN .alpha.-2. The present invention also includes crystalline metal-alfa interferon having monoclinic, plate and needle morphologies.
    Type: Grant
    Filed: February 25, 1993
    Date of Patent: August 15, 1995
    Assignee: Schering Corporation
    Inventors: Paul Reichert, Charles McNemar, Nagamani Nagabhushan, Tattanahalli L. Nagabhushan, Stephen Tindall, Alan Hruza
  • Purification of GM-CSF
    Patent number: 5391706
    Abstract: A method of purifying granulocyte-macrophage colony-stimulating factor (GM-CSF), particularly recombinant human GM-CSF, in good yield and with retention of biological activity, comprising sequential anion-exchange, dye-ligand affinity, gel filtration and reversed-phase chromatography is disclosed.
    Type: Grant
    Filed: September 21, 1993
    Date of Patent: February 21, 1995
    Assignee: Schering Plough Corporation
    Inventors: Paul P. Trotta, Gail F. Seelig, Robert A. Kosecki, Paul Reichert
  • Use of interleukin-4- for lowering blood-cholesterol levels
    Patent number: 5188827
    Abstract: A method for lowering the blood-serum cholesterol levels in mammals by administering IL-4 is disclosed as well as the use of IL-4 for the manufacture of a medicament for use in lowering blood-serum cholesterol levels.
    Type: Grant
    Filed: June 10, 1991
    Date of Patent: February 23, 1993
    Assignee: Schering Corporation
    Inventor: Hugh E. Black
  • Method for measuring the BZ-1 receptor binding activity in a test sample or test compound
    Patent number: 4997771
    Abstract: The invention describes a method for determining the BZ-1 receptor activity of a test sample or a potential anxiolytic drug.
    Type: Grant
    Filed: April 27, 1987
    Date of Patent: March 5, 1991
    Assignee: Schering Corporation
    Inventors: Allen Barnett, William Billard, Gordon Crosby, Jr., Louis Iorio, Martin Steinman